BRKR
Bruker Corporation
Is BRKR Halal?
Scientific-instrument and analytical-measurement manufacturing — generally permissible activity whose known current asset-based ratios pass, with activity classification incomplete.
What You Should Know
Bruker's March 31, 2026 Form 10-Q reports assets of $6,130.7 million, debt of $1,671.3 million, cash of $133.4 million, receivables of $542.7 million and quarterly revenue of $823.4 million. Debt/assets is 27.26%, liquidity/assets is 2.18%, receivables plus cash/assets is 11.03% and disclosed interest income is 0.60% of revenue. Known asset-based ratios pass, but no universal prohibited-revenue numerator is disclosed.
⚠️ Concerns
- •Known asset-based ratios pass, but no universal prohibited-revenue numerator is disclosed
- •Acquisition-related debt and goodwill require continuing review
- •Scientific instruments serve mixed research, clinical and industrial end uses
- •Disclosed interest income is 0.60% of quarterly revenue; no fixed purification percentage asserted
- •Foreign-exchange and research-spending cycles can change the profile
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
1,671.3 / 6,130.7
133.4 / 6,130.7
676.1 / 6,130.7
4.9 / 823.4
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 27.26%, liquidity/assets is 2.18%, receivables-plus-cash/assets is 11.03% and disclosed interest income is 0.60%; business activity remains qualitative.
- Financial
- Pass
- Overall
- Incomplete
Debt, liquidity and receivables-plus-cash ratios are below the examined MSCI limits; this is not an index-membership claim and activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and identifiable liquidity/assets are below the examined Malaysia limits; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Bruker designs and manufactures scientific instruments and analytical systems including magnetic resonance, mass spectrometry, X-ray, microscopy and spectroscopy tools for research, life-science and applied markets. The core activity is generally permissible, but the filing does not provide a universal prohibited-revenue numerator for downstream uses.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed; end-market use remains qualitative.
Purification
The filing discloses $4.9 million of interest income; ZakatInvest does not prescribe a fixed scholar-approved purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from Bruker's March 31, 2026 Form 10-Q.
- Current long-term debt and finance-lease obligations are $8.4 million and long-term debt is $1,662.9 million; operating leases are excluded.
- Cash and cash equivalents are $133.4 million; no separately identified interest-bearing security balance is added; receivables, net are $542.7 million.
- First-quarter revenue is $823.4 million and reported interest income is $4.9 million (0.60% of revenue).
- Scientific-instrument activity is retained as qualitative analysis; no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →